Literature DB >> 7054072

Drugs as indicators of hepatic function.

R A Branch.   

Abstract

It is well recognized that liver disease may influence the disposition of many drugs. Conversely, it has been suggested that knowledge of the disposition of a model drug might provide an index of certain aspects of hepatic function. This review discusses the physiology of drug disposition and indicates how recent progress in understanding the determinants of drug disposition has provided useful indices of individual aspects of hepatic function. Topics which are discussed are the interpretation of pharmacokinetic parameters as indices of hepatic function, including half-life clearance, and intrinsic clearance. Utilizing the "intact hepatocyte hypothesis" as an operational model, an approach is described that uses the pharmacokinetic disposition of high and low intrinsic clearance drugs following p.o. and i.v. administration to provide quantitative estimates of hepatic function, flow to functioning hepatocytes, and the extent of portasystemic shunting through the liver. Thus, the theoretical basis for quantitation of certain aspects of hepatic function are available. It remains to be determined whether these indices will provide clinically useful measures to follow the natural history of hepatic disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7054072     DOI: 10.1002/hep.1840020115

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

6.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Authors:  M Abei; E Tanaka; N Tanaka; Y Matsuzaki; T Ikegami; A Ishikawa; T Osuga
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

8.  Pharmacokinetics of encainide in patients with cirrhosis.

Authors:  G Wensing; H Mönig; E E Ohnhaus; H P Hoensch
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

9.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.